Michael Sernyak Jr, MD
Professor of Psychiatry; Deputy Chair for Clinical Affairs and Program Development, Department of Psychiatry; CEO, Connecticut Mental Health Center
Research & Publications
Biography
News
Coauthors
Selected Publications
- Administrative Best Practices in Public PsychiatryBarkil-Oteo A, Bailey M, Cole R, Delphin-Rittmon M, Devine S, Jacobs S, Steiner J, Trevisan L, Sernyak M. Administrative Best Practices in Public Psychiatry. 2016, 261-272. DOI: 10.1093/med/9780190214678.003.0018.
- Integrated Health CareAnnamalai A, Tek C, Sernyak M, Cole R, Steiner J. Integrated Health Care. 2016, 63-80. DOI: 10.1093/med/9780190214678.003.0005.
- Introduction and SignificanceJacobs S, Ball S, Davidson L, Díaz E, DeSanto Iennaco J, McMahon T, Rohrbaugh R, Steiner J, Styron T, Sernyak M, Zonana H. Introduction and Significance. 2016, 1-12. DOI: 10.1093/med/9780190214678.003.0001.
- Conclusion and Future ChallengesJacobs S, Ball S, Davidson L, Díaz E, DeSanto Iennaco J, McMahon T, Rohrbaugh R, Steiner J, Styron T, Sernyak M, Zonana H. Conclusion and Future Challenges. 2016, 273-286. DOI: 10.1093/med/9780190214678.003.0019.
- The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical CenterHermes E, Sernyak M, Rosenheck R. The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans Health Administration Medical Center. Epidemiology And Psychiatric Sciences 2013, 23: 281-288. PMID: 24007653, PMCID: PMC6998245, DOI: 10.1017/s2045796013000449.
- Generic Fluoxetine and Choice of Antidepressant MedicationSernyak M, Rosenheck R. Generic Fluoxetine and Choice of Antidepressant Medication. Psychiatric Services 2007, 58: 128-130. DOI: 10.1176/ps.2007.58.1.128.
- Predictors of Antipsychotic Medication ChangeSernyak M, Leslie D, Rosenheck R. Predictors of Antipsychotic Medication Change. The Journal Of Behavioral Health Services & Research 2005, 32: 85???94. DOI: 10.1097/00075484-200501000-00007.
- Clozapine in prevention of suicide in patients with schizophrenia: profile reportSernyak M. Clozapine in prevention of suicide in patients with schizophrenia: profile report. Drugs & Therapy Perspectives 2003, 19: 5-6. DOI: 10.2165/00042310-200319080-00002.
- Clozapine and Prevention of Suicide in SchizophreniaSernyak M. Clozapine and Prevention of Suicide in Schizophrenia. CNS Drugs 2003, 17: 281-281. DOI: 10.2165/00023210-200317040-00006.
- Dr. Sernyak and Colleagues ReplySERNYAK M, LESLIE D, ALARCON R, LOSONCZY M, ROSENHECK R. Dr. Sernyak and Colleagues Reply. American Journal Of Psychiatry 2003, 160: 389-389. DOI: 10.1176/appi.ajp.160.2.389.
- Dr. Sernyak and Colleagues ReplySERNYAK M, DESAI R, ROSENHECK R. Dr. Sernyak and Colleagues Reply. American Journal Of Psychiatry 2002, 159: 324-324. DOI: 10.1176/appi.ajp.159.2.324.
- Consistency of atypical antipsychotic superiority to placebo in recent clinical trialsWoods S, Stolar M, Sernyak M, Charney D. Consistency of atypical antipsychotic superiority to placebo in recent clinical trials. Biological Psychiatry 2001, 49: 64-70. PMID: 11163781, DOI: 10.1016/s0006-3223(00)00973-2.
- Benzodiazepine Use in Posttraumatic Stress Disorder among Veterans with Substance AbuseKOSTEN T, FONTANA A, SERNYAK M, ROSENHECK R. Benzodiazepine Use in Posttraumatic Stress Disorder among Veterans with Substance Abuse. The Journal Of Nervous And Mental Disease 2000, 188: 454-459. PMID: 10919705, DOI: 10.1097/00005053-200007000-00010.
- Clozapine and SuicideSernyak M, Hoff R, Rosenheck R. Clozapine and Suicide. Psychiatric Services 1999, 50: 116-116. PMID: 9890596, DOI: 10.1176/ps.50.1.116.
- Naltrexone Augmentation of Neuroleptics in SchizophreniaSernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.
- 435. Dose-response of THC effects in schizophrenics and healthy controlsD'Souza D, Belger A, Abi-Saab W, Adams S, Gil R, Larvey K, Cassello K, Sernyak M, Krystal J. 435. Dose-response of THC effects in schizophrenics and healthy controls. Biological Psychiatry 1998, 43: s130-s131. DOI: 10.1016/s0006-3223(98)90883-6.
- Leukopenia associated with addition of paroxetine to clozapine.George T, Innamorato L, Sernyak M, Baldessarini R, Centorrino F. Leukopenia associated with addition of paroxetine to clozapine. The Journal Of Clinical Psychiatry 1998, 59: 31. PMID: 9491066, DOI: 10.4088/jcp.v59n0107d.
- Effects of Acute Tryptophan Depletion in Lithium-Remitted Manic Patients: A Pilot StudyCappiello A, Sernyak M, Malison R, McDougle C, Heninger G, Price L. Effects of Acute Tryptophan Depletion in Lithium-Remitted Manic Patients: A Pilot Study. Biological Psychiatry 1997, 42: 1076-1078. PMID: 9386862, DOI: 10.1016/s0006-3223(97)00329-6.
- Cost-effectiveness of divalproex versus lithium.Baker C, Woods S, Sernyak M. Cost-effectiveness of divalproex versus lithium. The Journal Of Clinical Psychiatry 1997, 58: 363-4. PMID: 9515977, DOI: 10.4088/jcp.v58n0806d.
- 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopyBehar K, Rothman D, D’Souza D, Gil R, Petroff O, Abi-Saab D, Zuzarte E, Hooten M, Petrakis I, Sernyak M, White J, Webb E, Charnay D, Krystal J. 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopy. Schizophrenia Research 1997, 24: 175-176. DOI: 10.1016/s0920-9964(97)82504-2.
- 584 Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patientsDiaz E, Levine H, Sullivan M, Sernyak M, Hawkins K, Cramer J, Woods S. 584 Quantitative measurement of antipsychotic medication compliance in chronic schizophrenic patients. Schizophrenia Research 1997, 24: 206. DOI: 10.1016/s0920-9964(97)82592-3.
- Near syncope associated with concomitant clozapine and cocaine use.Hameedi F, Sernyak M, Navui S, Kosten T. Near syncope associated with concomitant clozapine and cocaine use. The Journal Of Clinical Psychiatry 1996, 57: 371-2. PMID: 8752022.
- Agranulocytosis after addition of risperidone to clozapine treatmentGodleski L, Sernyak M. Agranulocytosis after addition of risperidone to clozapine treatment. American Journal Of Psychiatry 1996, 153: 735b-736. PMID: 8615431, DOI: 10.1176/ajp.153.5.735b.
- Schizophrenia and StrabismusKrakauer E, Goldstein L, Sernyak M, Woods S. Schizophrenia and Strabismus. The Journal Of Nervous And Mental Disease 1995, 183: 662. PMID: 7561813, DOI: 10.1097/00005053-199510000-00008.
- Effects of clozapine on smoking in chronic schizophrenic outpatients.George T, Sernyak M, Ziedonis D, Woods S. Effects of clozapine on smoking in chronic schizophrenic outpatients. The Journal Of Clinical Psychiatry 1995, 56: 344-6. PMID: 7635849.
- Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjectsAbi-Dargham A, Krystal J, Laruelle M, D'Souza D, Zoghbi S, Brenner L, Gil R, Sernyak M, Baldwin R, Zubal G, Hoffer P, Charney D, Innis R. Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects. Schizophrenia Research 1995, 15: 75. DOI: 10.1016/0920-9964(95)95236-3.
- Neuroleptic exposure following inpatient treatment of acute mania with lithium and neurolepticSernyak M, Griffin R, Johnson R, Pearsall H, Wexler B, Woods S. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. American Journal Of Psychiatry 1994, 151: 133-135. PMID: 7903511, DOI: 10.1176/ajp.151.1.133.
- Chronic neuroleptic use in manic-depressive illness.Sernyak M, Woods S. Chronic neuroleptic use in manic-depressive illness. Psychopharmacology Bulletin 1993, 29: 375-81. PMID: 7907185.